A Novel First-in-Class Microbiome-Restoration Therapy for the Prevention of Recurrence of C. diff Infection
Newsroom
Thursday, 06 March 2025
Ferring Inc. Receives Health Canada Approval for REBYOTA® (fecal microbiota, live)
Toronto, ON – 6 March, 2025 – Ferring Inc. today announced that Health Canada has issued a Notice of Compliance, approving REBYOTA® (fecal microbiota, live), a novel first-in-class microbiome-restoration therapy indicated for the prevention of recurrence of Clostridioides difficile infection (C. diff) in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff. A Novel First-in-Class Microbiome-Restoration Therapy for the Prevention of Recurrence of C. diff Infection